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Abstract
Background: Global brain ischemia-reperfusion during propofol anesthesia provokes persistent cerebral pial
constriction. Constriction is likely mediated by Rho-kinase. Cerebral vasoconstriction possibly exacerbates
ischemic brain injury. Because Y-27632 is a potent Rho-kinase inhibitor, it should be necessary to evaluate its
effects on cerebral pial vessels during ischemia—reperfusion period. We therefore tested the hypotheses that
Y-27632 dilates cerebral pial arterioles after the ischemia-reperfusion injury, and evaluated the time-course of
cerebral pial arteriolar status after the ischemia-reperfusion.
Methods: Japanese white rabbits were anesthetized with propofol, and a closed cranial window inserted over
the left hemisphere. Global brain ischemia was produced by clamping the brachiocephalic, left common
carotid, and left subclavian arteries for 15 min. Rabbits were assigned to cranial window perfusion with: (1)
artificial cerebrospinal fluid (Control group, n = 7); (2) topical infusion of Y-27632 10−6 mol · L−1 for 30 min
before the initiation of global brain ischemia (Pre group, n = 7); (3) topical infusion of Y-27632 10−6 mol · L−1
starting 30 min before ischemia and continuing throughout the study period (Continuous group, n = 7); and,
(4) topical infusion of Y-27632 10−6 mol · L−1 starting 10 min after the ischemia and continuing until the end
of the study (Post group, n = 7). Cerebral pial arterial and venule diameters were recorded 30 min before
ischemia, just before arterial clamping, 10 min after clamping, and 5, 10, 20, 40, 60, 80, 100, and 120 min
after unclamping.
Results: Mean arterial blood pressure and blood glucose concentration increased significantly after global brain
ischemia except in the Continuous group. In the Pre and Continuous groups, topical application of Y-27632 produced
dilation of large (mean 18–19%) and small (mean; 25–29%) pial arteries, without apparent effect on venules. Compared
with the Control and Pre groups, arterioles were significantly dilated during the reperfusion period in the Continuous
and Post groups (mean at 120 min: 5–8% in large arterioles and 11–12% in small arterioles).
Conclusions: Y-27632 dilated cerebral pial arterioles during reperfusion. Y-27632 may enhance recovery from ischemia
by preventing arteriolar vasoconstriction during reperfusion.
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Background
Rho-kinase moderates many cellular functions including
adhesion, morphology, proliferation and motility, and also
smooth muscle contraction [1, 2]. A key step in smooth
muscle contraction is phosphorylation of myosin light chain
(MLC) by MLC kinase which is activated by Ca2+-calmodu-
lin complex. MLC is dephosphorylated by MLC phosphat-
ase. Rho-kinase enhances MLC phosphorylation and
mediates vascular contraction [3]. Rho-kinase inhibitors
thus attenuate MLC phosphorylation and inhibit smooth
muscle contractility. Fasudil is a clinically available Rho-
kinase inhibiter that reportedly increases cerebral blood
flow [4]. Y-27632, another Rho-kinase inhibiter, dilates
normal basilar arterioles [5] and cerebral pial arterioles [6].
Propofol is a commonly used anesthetic drug. Surgeries
such as temporary arterial clipping during cerebral
aneurysm surgery, carotid endarterectomy, repair of aortic
arch aneurysm, unexpected cardiac arrest, etc. are clinical
scenarios in which brain ischemia and reperfusion could
occur under propofol anesthesia. Global brain ischemia-
reperfusion during propofol anesthesia provokes persist-
ent cerebral pial constriction [7]. Cerebral vasocon-
striction possibly exacerbates ischemic brain injury [8].
Rho-kinase is activated in endothelial cells during cerebral
ischemia and apparently contributes to consequent micro-
circulatory disturbances [9]. Fasudil, a Rho-kinase inhibi-
ter, prevents cerebral vasospasm and reduces blood
viscosity, and has been used therapeutically in patients
with subarachnoid hemorrhage [10]. In addition, vasodila-
tion after brain ischemia may provide sufficient oxygen
and glucose and may remove acidic metabolites from the
ischemic brain tissue for preservation of normal neuronal
function [11]. Because cerebral vasodilation may help
maintain brain perfusion during the vasoconstrictive
phase of ischemia-reperfusion injury, it is important to
evaluate the vasodilatory effect of Rho-kinase inhibitors
during the global brain ischemia and reperfusion period.
We investigated the effect of Y-27632, a Rho-kinase in-
hibitor, on the cerebral pial arterial diameter changes during
brain ischemia-reperfusion period using cranial windows in
rabbits. Specifically, we evaluated the effects of application
period of Y-27632 (before the ischemia, continuously during
the study period, and after the ischemia) on ischemia-
induced pial arteriolar diameter changes. Our hypotheses
were that: 1) Y-27632 dilates cerebral pial arterioles during
ischemia and reperfusion; 2) continuously applied Y-27632
produces maximum cerebral pial arteriolar dilation; and 3)
Y-27632 restricted to the reperfusion period produces less
cerebral pial arteriole vasodilation than continuous applica-
tion throughout ischemia and reperfusion.
Methods
This study was approved by the Committee on Animal Re-
search at the University of Yamanashi, Japan. Experiments
were performed on 28 Japanese white rabbits weighing
3.2–3.8 kg. After obtaining IV access in an ear vein, the ani-
mals were anesthetized with propofol (8 mg∙kg−1 IV bolus
followed by an infusion of 36 mg∙kg−1∙h−1) [12]. A tracheos-
tomy was performed and their lungs mechanically venti-
lated with an oxygen-air mixture.
End-tidal carbon dioxide tension (ETCO2) was continu-
ously monitored (Vamos, Dräger medical, Tokyo, Japan).
Based on ETCO2 measurements, the tidal volume and
respiratory rate were adjusted to maintain arterial carbon
dioxide tension (PaCO2) between 35 and 45 mmHg. A
femoral-artery catheter allowed continuous monitoring of
mean arterial blood pressure (MAP) and blood sampling.
Bicarbonated Ringer’s solution (Bicarbon, Ajinomoto,
Tokyo, Japan) was infused at 10 mL∙kg−1∙h−1.
After exposing the aortic arch, the brachiocephalic, left
common carotid, and left subclavian arteries were iso-
lated, and the rabbits were placed in the sphinx posture.
A closed cranial window was implanted over the parietal
cortex. With the scalp retracted, an 8-mm-diameter hole
was made in the parietal bone. The dura and arachnoid
membranes were cut; a ring with thin glass was then po-
sitioned over the hole and secured with bone wax and
dental acrylic. The space under the window was filled
with artificial cerebrospinal fluid (aCSF), which was
composed with Na+ 151 mEq∙L−1, K+ 3.5 mEq∙L−1, Ca2+
2.5 mEq∙L−1, Mg2+ 1.3 mEq∙L−1, HCO3
− 25 mEq∙L−1, urea
40 mg∙dL−1, and glucose 65 mg∙dL−1.
Three polyethylene catheters were inserted into the
ring. One catheter was attached to a reservoir bottle
containing aCSF which was continuously bubbled with
5% CO2 in air. The aCSF was suffused at 0.1 mL∙min
−1.
Other catheters served as an outlet for aCSF, and the
third port measured pressure in the window. The level
of the outlet was maintained approximately 5–6 cm
above the window, thus the intracranial pressure was
maintained at 5–6 cm H2O. The volume of fluid below
the window was between 0.5 and 0.7 mL. Global brain
ischemia was produced by simultaneously clamping the
brachiocephalic, left common carotid, and left subclavian
arteries for 15 min. It has been reported that, in gerbils,
during the global ischemia-reperfusion period, there is a
short phase of vasodilation followed by a prolonged
phase of vasoconstriction [13]. We previously reported
that pial arterioles were dilated temporarily and were
constricted thereafter in the 15 min of global cerebral is-
chemia in rabbits [7]. Therefore, we employed 15 min of
global brain ischemia.
Twenty-eight rabbits were assigned randomly to one
of four groups with 7 rabbits per group. A sample-size
estimate analysis indicated that 7 rabbits per group was
sufficient to detect a 15% change in pial arteriolar diam-
eter from the control values with a power of 0.8 and α <
0.05. In the Control group, artificial cerebrospinal fluid
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was infused into the cranial windows. In the Pre group,
Y-27632 at 10−6 mol∙L−1 was infused from 30 min before
the initiation of global brain ischemia for 30 min. Then
artificial cerebrospinal fluid was infused during the
ischemia-reperfusion period. In the Continuous group,
Y-27632 at 10−6 mol∙L−1 was infused from 30 min before
the global brain ischemia to 120 min after unclamping.
In the Post group, Y-27632 at 10−6 mol∙L−1 was infused
from 10 min after the global brain ischemia started until
120 min after unclamping. In our previous study, Y-
27632 at 10−6 mol∙L−1 produced substantial cerebral pial
arteriolar dilation [6]. On the basis of this dose-ranging
study, we thus selected 10−6 mol∙L−1 as the concentra-
tion of Y-27632 for the current study.
Measurements of cerebral pial diameters were made
at the following time-points: 30 min before global
brain ischemia (baseline), just before global brain is-
chemia, 10 min after global brain ischemia, and at 5,
10, 20, 40, 60, 80, 100, 120 min after reperfusion.
The diameters of 3–4 pial microvessels as available
within each window were measured in each cranial
window. Images of pial vessels were captured and
recorded on a personal computer attached to a
microscope (VH-5000, Keyence, Osaka, Japan) via
video capture unit (VH-E500, Keyence, Osaka, Japan).
The microscopic magnification was × 150. The reso-
lution of the video system was 1600 × 1200 pixels.
Diameters of pial vessels were measured off line using
a digital video analyzer (VH Analyzer VH-H1A5, Key-
ence, Osaka, Japan) on a personal computer. The
sizes of arterioles and venules were divided on the
basis of initial diameters into 2 subgroups, > 70
(large), and ≤ 70 (small) micrometers. After the com-
pletion of the measurements, animals were euthanized
by injection of potassium chloride in deep anesthesia
with propofol.
Statistical analysis
Results are presented as means ± SDs. Within-group com-
parisons in MAP, HR, body temperature, arterial blood
pH, PaCO2, PaO2, and plasma concentrations of Na
+, K+,
glucose, and lactate in each experimental group were per-
formed using repeated measures analysis of variance
(ANOVA) and Dunnett’s post hoc testing. Cerebral pial
vascular percent changes in diameter from the baseline in
each group were examined via repeated measures
ANOVA and Dunnett’s post hoc testing. Among-group
comparisons were performed using factorial ANOVA and
Newman Keuls post hoc testing. A P value less than 0.05
was considered statistically significant.
Power analysis indicated that a sample size of 7 rabbits
per group was sufficient to detect a 15% change in pial
arteriolar diameter from the control values with a power
of 0.8 and α < 0.05. The primary outcome was average
dilation of cerebral pial arterioles in response to Y-27632
during ischemia (Control and Post groups versus Pre
and Continuous groups) and reperfusion (Control and
Pre groups versus Continuous and Post groups). The
secondary outcome was average pial arteriolar dilation
over time depending on the timing of initiation of Y-
27632 administration.
Results
Mean arterial blood pressure (MAP) increased signifi-
cantly, by about 27–39 mmHg, after clamping the
brachiocephalic artery, left common carotid artery, and
left subclavian artery in the Control, the Pre, and the
Post groups. In contrast, heart rate (HR) remained
largely unchanged in all groups. After unclamping, MAP,
HR, and base excess decreased. Plasma glucose in-
creased significantly in the Control, the Pre, and the Post
groups (Tables 1, 2, 3 and 4). Physiologic variables were
not different among the four groups.
Table 1 Physiologic measurements in the control group
MAP HR pH PaCO2 PaO2 Base excess Na K Glucose
(mm Hg) (bpm) (mm Hg) (mm Hg) (mEq/L) (mEq/L) (mEq/L) (mg/dL)
baseline 107 ± 13 281 ± 47 7.36 ± 0.04 42 ± 5 199 ± 26 −2.0 ± 3.0 138 ± 3 3.7 ± 0.3 133 ± 19
clamp 10 min 144 ± 15* 269 ± 66 7.33 ± 0.06 42 ± 6 199 ± 17 −4.0 ± 1.7 136 ± 6 4.1 ± 0.9 212 ± 48*
declamp5min 98 ± 21 259 ± 59 7.32 ± 0.08 43 ± 7 204 ± 22 −4.3 ± 1.8 137 ± 4 3.7 ± 0.4 205 ± 29*
declamp10min 103 ± 9 272 ± 46 7.31 ± 0.07 44 ± 6 204 ± 22 −4.6 ± 2.2 136 ± 6 3.7 ± 0.4 211 ± 37*
declamp 20 min 104 ± 8 271 ± 38 7.31 ± 0.08 44 ± 7 194 ± 38 −4.3 ± 2.5 137 ± 3 3.8 ± 0.4 171 ± 52
declamp 40 min 98 ± 15 275 ± 38 7.34 ± 0.06 43 ± 7 198 ± 43 −2.9 ± 1.9 137 ± 3 3.8 ± 0.3 164 ± 47
declamp 60 min 103 ± 10 276 ± 67 7.35 ± 0.05 42 ± 6 203 ± 38 −2.6 ± 1.8 136 ± 5 3.9 ± 0.5 148 ± 35
declamp 80 min 103 ± 12 280 ± 32 7.37 ± 0.04 39 ± 5 202 ± 39 −2.6 ± 2.3 136 ± 7 4.1 ± 0.8 140 ± 30
declamp 100 min 104 ± 11 284 ± 32 7.36 ± 0.04 41 ± 5 196 ± 48 −2.3 ± 1.8 136 ± 6 4.1 ± 0.6 146 ± 30
declamp 120 min 106 ± 14 279 ± 40 7.36 ± 0.05 40 ± 6 193 ± 46 −3.0 ± 2.8 135 ± 6 4.1 ± 1.0 147 ± 40
Values are mean ± SD
MAP mean arterial blood pressure, HR heart rate, baseline before ischemia
* P < 0.05 compared with the values at baseline
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In the Pre and Continuous groups, topical application of
Y-27632 at 10−6 mol∙L−1 produced large and small pial ar-
teriolar and small venular dilation (Figs. 1b, c, 2b, c, and 4b),
but did not significantly dilate venules (Figs. 3b, c, and 4c).
During ischemia, large and small pial arterioles were
constricted in the Control and the Post groups
(Figs. 1a, d, and 2a), but remained largely unchanged
compared to baseline in the Pre and the Continuous
groups (Figs. 1b, c, 2b, and c). Pial large and small
venules were slightly constricted but not statistically
significant in all groups (Figs. 3 and 4).
During reperfusion in the Control group, significant
constriction was observed in both large and small arteri-
oles (Figs. 1a and 2a). In the Pre group, large arterioles
were constricted, but not significantly (Fig. 1b). In
contrast, pial arterioles were dilated in the Continuous
and Post groups (Figs. 1c, d, 2c, and d). Small venular di-
ameters increased temporarily after unclamping but
otherwise remained largely unchanged during reperfu-
sion in all groups (Figs. 3 and 4).
Discussion
In this study, we observed that topical application of Y-
27632 at 10−6 mol∙L−1 produced large and small pial
arteriolar dilation, but did not induce venular dilation.
Without Y-27632, pial arterioles were constricted at the
ischemia, and were temporarily dilated and then were
significantly constricted at the reperfusion period. These
results concur with our previous studies [6, 7]. When Y-
27632 was applied only before the global cerebral ische-
mia, pial arterioles were not constricted at the ischemia,
and were temporarily dilated and then were constricted
but not significantly at the reperfusion period. When Y-
27632 was applied throughout the study period, pial
arterioles were not constricted at the ischemia, and were
dilated at the reperfusion period. When Y-27632 was
Table 2 Physiologic measurements in the pre group
MAP HR pH PaCO2 PaO2 Base excess Na K Glucose
(mm Hg) (bpm) (mm Hg) (mm Hg) (mEq/L) (mEq/L) (mEq/L) (mg/dL)
baseline 112 ± 15 266 ± 31 7.38 ± 0.03 41 ± 3 214 ± 50 −1.2 ± 2.8 139 ± 1 3.4 ± 0.4 144 ± 15
clamp 10 min 139 ± 25* 258 ± 39 7.31 ± 0.04 44 ± 4 193 ± 29 −4.1 ± 2.6 138 ± 2 3.8 ± 0.2 207 ± 55*
declamp5min 87 ± 10 236 ± 29 7.29 ± 0.04 46 ± 4 200 ± 28 −4.6 ± 1.9 138 ± 2 3.6 ± 0.3 228 ± 70*
declamp10min 95 ± 16 230 ± 27 7.29 ± 0.03 44 ± 4 201 ± 28 −5.5 ± 2.8 138 ± 2 3.6 ± 0.4 217 ± 64*
declamp 20 min 102 ± 20 235 ± 16 7.30 ± 0.03 43 ± 4 202 ± 26 −5.3 ± 2.3 137 ± 1 3.7 ± 0.4 209 ± 64*
declamp 40 min 105 ± 16 239 ± 22 7.32 ± 0.03 41 ± 4 206 ± 24 −5.0 ± 2.7 136 ± 2 3.8 ± 0.6 197 ± 73
declamp 60 min 105 ± 14 241 ± 28 7.33 ± 0.03 41 ± 5 206 ± 27 −4.5 ± 3.1 136 ± 2 4.0 ± 0.8 184 ± 73
declamp 80 min 101 ± 15 238 ± 19 7.33 ± 0.04 41 ± 3 204 ± 25 −4.3 ± 2.9 135 ± 2 4.1 ± 1.1 186 ± 67
declamp 100 min 104 ± 14 235 ± 23 7.33 ± 0.04 41 ± 3 187 ± 25 −4.2 ± 2.7 135 ± 3 4.2 ± 1.3 185 ± 66
declamp 120 min 104 ± 10 235 ± 33 7.32 ± 0.04 42 ± 2 183 ± 34 −4.2 ± 2.6 135 ± 3 4.3 ± 1.4 186 ± 62
Values are mean ± SD
MAP mean arterial blood pressure, HR heart rate, baseline before ischemia
* P < 0.05 compared with the values at baseline
Table 3 Physiologic measurements in the continuous group
MAP HR pH PaCO2 PaO2 Base excess Na K Glucose
(mm Hg) (bpm) (mm Hg) (mm Hg) (mEq/L) (mEq/L) (mEq/L) (mg/dL)
baseline 110 ± 7 253 ± 44 7.40 ± 0.05 40 ± 3 189 ± 66 0.7 ± 2.7 137 ± 2 3.6 ± 0.3 139 ± 17
clamp 10 min 110 ± 46 229 ± 32 7.37 ± 0.06 43 ± 5 154 ± 75 −0.6 ± 2.5 138 ± 2 3.9 ± 0.4 163 ± 44
declamp5min 78 ± 36 213 ± 35 7.34 ± 0.08 45 ± 7 163 ± 63 −1.8 ± 3.0 137 ± 2 3.8 ± 0.5 159 ± 49
declamp10min 77 ± 27 215 ± 30 7.33 ± 0.08 46 ± 11 155 ± 66 −1.6 ± 3.3 138 ± 2 3.8 ± 0.5 160 ± 45
declamp 20 min 79 ± 26 221 ± 22 7.33 ± 0.09 46 ± 14 148 ± 57 −2.4 ± 2.6 137 ± 2 4.0 ± 0.6 156 ± 42
declamp 40 min 88 ± 26 221 ± 27 7.36 ± 0.07 43 ± 10 169 ± 64 −2.0 ± 2.3 137 ± 3 4.2 ± 0.8 151 ± 38
declamp 60 min 90 ± 28 218 ± 20 7.37 ± 0.05 42 ± 6 170 ± 65 −1.2 ± 2.1 136 ± 2 4.4 ± 1.2 146 ± 31
declamp 80 min 86 ± 28 211 ± 28 7.38 ± 0.06 41 ± 5 168 ± 63 −1.2 ± 2.3 136 ± 2 4.5 ± 1.3 147 ± 37
declamp 100 min 90 ± 29 212 ± 32 7.37 ± 0.05 41 ± 4 168 ± 62 −1.5 ± 2.4 136 ± 3 4.6 ± 1.4 147 ± 42
declamp 120 min 87 ± 27 208 ± 31 7.38 ± 0.06 40 ± 4 162 ± 75 −1.8 ± 2.8 135 ± 2 4.6 ± 1.4 151 ± 45
Values are mean ± SD
MAP mean arterial blood pressure, HR heart rate, baseline before ischemia
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applied from 10 min after the global brain to the end of
the study, pial arterioles were constricted at the ische-
mia, and were dilated at the reperfusion period. Pial
venules remained largely unchanged during ischemia
and reperfusion period.
Generally, smooth muscle contraction is mediated by
intracellular Ca2+ concentration. Elevated intracellular Ca2+
complexes with calmodulin and activates MLC. Activated
myosin light chain kinase phosphorylates myosin light
chain and phosphorylated myosin light chain induces
smooth muscle contraction. The phosphorylation-state of
myosin light chain depends on the balance of myosin light
chain kinase activity and myosin light chain phosphatase
activity. Specifically, myosin light chain is dephosphorylated
Table 4 Physiologic measurements in the post group
MAP HR pH PaCO2 PaO2 Base excess Na K Glucose
(mm Hg) (bpm) (mm Hg) (mm Hg) (mEq/L) (mEq/L) (mEq/L) (mg/dL)
baseline 105 ± 8 252 ± 52 7.39 ± 0.04 42 ± 3 222 ± 43 0.6 ± 2.6 136 ± 2 3.7 ± 0.4 130 ± 24
clamp 10 min 144 ± 21* 255 ± 74 7.35 ± 0.06 42 ± 2 188 ± 40 −2.4 ± 4 135 ± 2 4.3 ± 1.0 188 ± 42*
declamp5min 99 ± 11 239 ± 64 7.31 ± 0.06 45 ± 3 203 ± 36 −3.0 ± 3.8 134 ± 2 3.9 ± 0.9 192 ± 47*
declamp10min 101 ± 12 248 ± 46 7.32 ± 0.07 44 ± 3 207 ± 36 −3.3 ± 3.9 135 ± 2 3.9 ± 1.0 195 ± 51*
declamp 20 min 102 ± 9 252 ± 42 7.34 ± 0.07 43 ± 3 210 ± 29 −2.7 ± 4.0 134 ± 3 4.0 ± 1.1 189 ± 56*
declamp 40 min 97 ± 12 256 ± 57 7.36 ± 0.06 42 ± 4 216 ± 24 −1.6 ± 3.8 133 ± 3 4.1 ± 1.2 172 ± 56
declamp 60 min 93 ± 4 255 ± 50 7.38 ± 0.07 41 ± 5 211 ± 28 −0.9 ± 3.6 134 ± 4 4.2 ± 1.2 152 ± 46
declamp 80 min 92 ± 18 233 ± 39 7.37 ± 0.06 40 ± 3 221 ± 25 −2.0 ± 2.1 133 ± 4 4.4 ± 1.1 147 ± 33
declamp 100 min 93 ± 16 257 ± 40 7.40 ± 0.07 39 ± 3 221 ± 28 −0.1 ± 3.8 133 ± 3 4.3 ± 1.2 140 ± 22
declamp 120 min 91 ± 10 257 ± 45 7.40 ± 0.06 39 ± 2 224 ± 32 −0.4 ± 3.5 132 ± 3 4.2 ± 1.1 136 ± 17
Values are mean ± SD
MAP mean arterial blood pressure, HR heart rate, baseline before ischemia
* P < 0.05 compared with the values at baseline
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Fig. 1 Percent changes in diameter in large (>70 μm) cerebral pial arterioles in the Control a, the Pre b, the Continuous c, and the Post d groups. Before
global brain ischemia, Y-27632 produced pial arteriolar dilation (b and c). In the Control group, pial arterioles were constricted during the ischemia, and
were dilated temporarily and then were constricted during the reperfusion period. In the Pre group, pial arterioles were not constricted during ischemia,
and were temporarily dilated during the reperfusion period. In the Continuous group, pial arterioles were not constricted during the ischemia, and were
dilated during the reperfusion period. In the Post group, pial arterioles were constricted during the ischemia, and were dilated during the reperfusion
period. Ba = baseline, Y = after the application of Y-27632, I = initiation of global brain ischemia. * P< 0.05, versus baseline, † P< 0.05, versus the Control
group, ‡ P< 0.05, versus the Pre group
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by activated myosin light chain phosphatase, with conse-
quent smooth muscle relaxation.
Rho-kinase mediates relaxation and contraction of
smooth muscle independently of intracellular Ca2+ concen-
tration [14–16]. Activated Rho-kinase inactivates myosin
light chain phosphatase. Myosin light chain is therefore
phosphorylated persistently and smooth muscle constricts.
We previously reported that Y-27632, a Rho-kinase inhibi-
tor, dilates cerebral pial arterioles [6]. As would thus be
expected, topical application of Y-27632 at 10−6 mol/L
dilated both large and small pial arterioles. Y-27632 is
reported to induce concentration-dependent reduction of
myogenic tone in the rabbit facial vein [17]. However, we
did not observe similar dilation of pial venules that is con-
sistent with our previous experience [6].
After brain ischemia of 15 min, pial arterioles and venules
dilated in the control group; however, the arterioles there-
after constricted which is consistent with our experience in
rabbits [7] and previous reports in mongolian gerbils [13].
Cerebral blood flow, which was measured by Laser Doppler
flowmetry, and pial vascular diameter, which was measured
with cranial window, are reported to change similarly [13].
Large intracranial and extracerebral vessels are a major site
of regulating cerebral blood flow [18]. Therefore, vessels
within the brain should respond similarly to pial vessels.
Arteriolar constriction is associated with reduced capillary
flow [13], and hypoperfusion after brain ischemia appears
to contribute to development of cerebral edema [19]
Additionally, Rho-kinase has been reported to be activated
in the endothelial cells and contributes to microcirculatory
disturbances in cerebral ischemia [9]. Rho-kinase may thus
be a therapeutic target for ischemic stroke [4].
Pial arteriolar responses in the pre-application group
were similar to those in the control group. In the Pre
group, artificial cerebrospinal fluid was infused followed
by the Y-27632 application. In the cranial window
technique, drug's effect on pial arterioles is attenuated
several minutes after the discontinuation of drug admi-
nistration. It is therefore unsurprising that application of
Y-27632 restricted to before ischemia did not produce
vasodilation during reperfusion. In contrast, continuous
application of Y-27632 before and during ischemia-
reperfusion produced pial arteriolar dilation before and
after ischemia-reperfusion. Consistent with this observa-
tion, Rho-kinase inhibition acutely augments blood flow
in focal cerebral ischemia [20] and fasudil is antivasos-
pastic in the context of subarachnoid hemorrhage [10].
In most clinical situations, brain ischemia cannot be
reliably predicted. It is thus of considerable interest to
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Fig. 2 Percent changes in diameter in small (≤70 μm) cerebral pial arterioles in the Control a, the Pre b, the Continuous c, and the Post d groups. Before
global brain ischemia, Y-27632 produced pial arteriolar dilation (b and c). In the Control group, pial arterioles were constricted during the ischemia, and were
dilated temporarily and then were constricted during the reperfusion period. In the Pre group, pial arterioles were not constricted during ischemia, and were
temporarily dilated during the reperfusion period. In the Continuous group, pial arterioles were not constricted during the ischemia, and were dilated during
the reperfusion period. In the Post group, pial arterioles were constricted but not statistically significant during the ischemia, and were dilated during the
reperfusion period. Ba = baseline, Y = after the application of Y-27632, I = initiation of global brain ischemia. * P< 0.05, versus baseline, † P<0.05, versus the
Control group
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A B
C D
Fig. 3 Percent changes in diameter in large (>70 μm) cerebral pial venules in the Control a, the Pre b, the Continuous c, and the Post d groups.
Before global brain ischemia, Y-27632 did not produce pial venular dilation (b and c). Large venules remained unchanged during reperfusion in
all groups. Ba = baseline, Y = after the application of Y-27632, I = initiation of global brain ischemia
A B
C D
Fig. 4 Percent changes in diameter in small (≤70 μm) cerebral pial venules in the Control a, the Pre b, the Continuous c, and the Post d groups.
Before global brain ischemia, Y-27632 produced pial venular dilation b. During the ischemia, pial venules were slightly constricted but not
statistically significant in all groups. During the reperfusion period, pial venules were dilated temporarily in the Control and the Pre groups but
otherwise remained unchanged during reperfusion in all groups. Ba = baseline, Y = after the application of Y-27632, I = initiation of global brain
ischemia. * P < 0.05, versus baseline
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of brain ischemia. We assumed that post-ischemic
application of Y-27632 would produce less pial arteri-
olar dilation than application starting before ischemia.
However, the amount of arteriolar dilation was similar
under pre-ischemic and post-ischemic conditions,
suggesting that it may be useful to give Y-27632 even
after cerebral ischemia is identified. If we wish to leap
to a potential therapeutic use of Y-27632, we should
consider to administer it intravenously rather than
topically, which would not be a reasonable route for
clinical therapy.
Propofol is known to decrease the brain metabolism
that is coupled with decreases in cerebral blood flow,
though it has no pial vascular effects [21]. In the present
study and our previous study [7], pial arterioles were
dilated temporarily and were constricted continuously
during the reperfusion period under propofol anesthesia.
It is possible that propofol exaggerated the vasoconstric-
tion during reperfusion. We also showed in the previous
study that pial arterioles were dilated temporarily and
were not constricted during the reperfusion period
under sevoflurane anesthesia [7]. Sevoflurane is reported
to produce cerebral vasodilation via activation of adeno-
sine triphosphate-sensitive K+ channels [22]. Y-27632
and sevoflurane dilate pial vessels through different
mechanisms. If we would have used sevoflurane in this
study, Y-27632 may have exerted further dilating effects
on pial arterioles.
In the present study, the group that received continuous
application of Y-27632 had a reduced glucose response to
global brain ischemia. It has been reported that Y-27632
enhanced glucose-stimulated insulin secretion [23, 24].
We did not measure the quantity of Y-27632 absorbed
from the pial surface, when it was applied within the cra-
nial window. However, some quantity of Y-27632 should
have been absorbed from the pial surface to systemic cir-
culation and induced glucose-stimulated insulin secretion
at the global brain ischemia.
A limitation of our study is that cerebral blood flow was
not measured. Nevertheless, laminar flow is proportional
to 4th power of the vessel radius (Poiseuille's law), sug-
gesting that the observed arterioloar dilation (i.e., 20–30%
during reperfusion) markedly increased flow, perhaps by
2.0–2.9-fold. We did not include any histological analyses
which would have characterized the presumed benefit on
vasodilation on tissue. And finally, results in rabbits may
extrapolate poorly to humans.
Conclusions
Y-27632 dilated cerebral pial arterioles, but not dilate
pial venules before ischemia and reperfusion preriod.
Application of Y-27632 restricted to the pre-ischemic
period did not prevent subsequent arteriolar constriction
induced by ischemia-reperfusion. Both continuous
administration and post-ischemic application of Y-27632
counteracted persistent cerebral pial arteriolar constric-
tion during the reperfusion period. Continuous applica-
tion of Y-27632 may thus be useful regarding the
production of cerebral vasodilation after global brain
ischemia, but also appears beneficial when it is applied
after onset of ischemia.
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